Published in J Pharmacol Exp Ther on February 05, 2016
Placental control of drug delivery. Adv Drug Deliv Rev (2016) 0.75
Down-regulation of the placental BCRP/ABCG2 transporter in response to hypoxia signaling. Placenta (2017) 0.75
Expression of placental regulatory genes is associated with fetal growth. J Perinat Med (2017) 0.75
Localization of the placental BCRP/ABCG2 transporter to lipid rafts: Role for cholesterol in mediating efflux activity. Placenta (2017) 0.75
Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology (1998) 9.57
A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med (2000) 4.13
Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care (2007) 4.09
Increasing prevalence of gestational diabetes mellitus (GDM) over time and by birth cohort: Kaiser Permanente of Colorado GDM Screening Program. Diabetes Care (2005) 4.08
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res (2001) 4.05
Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol (2005) 2.58
Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology (1978) 2.42
Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011. Obstet Gynecol (2014) 2.11
C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther (2002) 1.95
Prevalence estimates of gestational diabetes mellitus in the United States, Pregnancy Risk Assessment Monitoring System (PRAMS), 2007-2010. Prev Chronic Dis (2014) 1.83
Modulators of cyclic AMP metabolism induce syncytiotrophoblast formation in vitro. Exp Cell Res (1990) 1.70
Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J Epidemiol (2000) 1.54
Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics (2003) 1.51
Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol (2004) 1.50
Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res (2004) 1.46
Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos (2004) 1.41
Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res (2004) 1.38
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2009) 1.38
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst (2006) 1.38
Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol (2005) 1.30
Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci (2002) 1.28
The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol Pharmacol (2007) 1.26
Soy isoflavones in the treatment of prostate cancer. Nutr Cancer (2003) 1.24
Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res (2004) 1.20
The functional regeneration of syncytiotrophoblast in cultured explants of term placenta. Am J Physiol Regul Integr Comp Physiol (2001) 1.20
Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol Pharmacol (2007) 1.18
Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells. Am J Physiol Endocrinol Metab (2005) 1.17
Hypoglycaemia of the newborn: a review. Bull World Health Organ (1997) 1.16
Perinatal outcomes and the use of oral hypoglycemic agents. J Perinat Med (2005) 1.15
Validation of a soy food-frequency questionnaire and evaluation of correlates of plasma isoflavone concentrations in postmenopausal women. Am J Clin Nutr (2003) 1.15
Bioavailability of the glucuronide and sulfate conjugates of genistein and daidzein in breast cancer resistance protein 1 knockout mice. Drug Metab Dispos (2011) 1.15
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther (2004) 1.13
Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci (2007) 1.11
Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol. Br J Pharmacol (2008) 1.10
The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010). Menopause (2011) 1.09
Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res (2005) 1.09
Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations. Pharm Res (2008) 1.09
ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast. Am J Physiol Regul Integr Comp Physiol (2005) 1.08
Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules. Proc Natl Acad Sci U S A (2013) 1.05
Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. Am J Obstet Gynecol (2006) 1.05
Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. Mol Cancer Ther (2004) 1.04
Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet Genomics (2008) 1.03
Wide-ranging DNA methylation differences of primary trophoblast cell populations and derived cell lines: implications and opportunities for understanding trophoblast function. Mol Hum Reprod (2011) 1.03
Comparison of glyburide versus insulin in management of gestational diabetes mellitus. Endocr Pract (2007) 1.03
The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. Placenta (2008) 1.02
Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta (2006) 1.01
Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. Am J Obstet Gynecol (2010) 1.00
Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. J Clin Endocrinol Metab (2003) 1.00
Phytoestrogen intake and prostate cancer: a case-control study using a new database. Nutr Cancer (1999) 1.00
Effects of isoflavone supplements vs. soy foods on blood concentrations of genistein and daidzein in adults. J Nutr Biochem (2008) 0.99
Breast cancer resistance protein: mediating the trans-placental transfer of glyburide across the human placenta. Placenta (2007) 0.99
International Transporter Consortium commentary on clinically important transporter polymorphisms. Clin Pharmacol Ther (2013) 0.99
A prospective study comparing insulin and glibenclamide in gestational diabetes mellitus in Asian Indian women. Diabetes Res Clin Pract (2006) 0.98
Inhibition of ATPase, GTPase and adenylate kinase activities of the second nucleotide-binding fold of the cystic fibrosis transmembrane conductance regulator by genistein. Biochem J (1999) 0.96
The soy isoflavone daidzein improves the capacity of tamoxifen to prevent mammary tumours. Eur J Cancer (2005) 0.95
Genistein in the metabolic syndrome: results of a randomized clinical trial. J Clin Endocrinol Metab (2013) 0.93
Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate. Toxicol Sci (2006) 0.92
Comparison of plasma and urinary phytoestrogens in Japanese and Finnish women by time-resolved fluoroimmunoassay. Biofactors (2000) 0.91
Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism. Drug Metab Dispos (2010) 0.90
Distinct effects of the antiestrogen Faslodex on the stability of estrogen receptors-alpha and -beta in the breast cancer cell line MCF-7. J Mol Endocrinol (2004) 0.90
Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep. J Vet Pharmacol Ther (2006) 0.90
Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J Med Chem (1999) 0.87
Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. J Pharm Sci (2012) 0.86
Regulation of leptin expression by 17beta-estradiol in human placental cells involves membrane associated estrogen receptor alpha. Biochim Biophys Acta (2012) 0.84
Genistein-inhibited cancer stem cell-like properties and reduced chemoresistance of gastric cancer. Int J Mol Sci (2014) 0.83
In vivo inhibition of BCRP/ABCG2 mediated transport of nitrofurantoin by the isoflavones genistein and daidzein: a comparative study in Bcrp1 (-/-) mice. Pharm Res (2010) 0.82
Distinct effects on the conformation of estrogen receptor alpha and beta by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability. Biochem Biophys Res Commun (1999) 0.82
Effect of oxygen on multidrug resistance in term human placenta. Placenta (2014) 0.80
Assessment of drug transporter function using fluorescent cell imaging. Curr Protoc Toxicol (2013) 0.80
Regulation of expression and activity of multidrug resistance proteins MRP2 and MDR1 by estrogenic compounds in Caco-2 cells. Role in prevention of xenobiotic-induced cytotoxicity. Toxicology (2014) 0.80
Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: an ex vivo study. Am J Obstet Gynecol (2013) 0.79
Induction of cells differentiation and ABC transporters expression by a myco-estrogen, zearalenone, in human choriocarcinoma cell line (BeWo). Toxicology (2009) 0.79
BCRP at the blood-brain barrier: genomic regulation by 17β-estradiol. Mol Pharm (2010) 0.79
Glyburide transport across the human placenta. Obstet Gynecol (2015) 0.77
MDR1 P-gp expression and activity in intact human placental tissue; upregulation by retroviral transduction. Placenta (2005) 0.77
Investigating the potential role of multi-drug resistance protein (MRP) transporters in fetal to maternal glyburide efflux in the human placenta. J Obstet Gynaecol (2008) 0.77
Synthesis and secretion of human chorionic gonadotropin and its subunits in choriocarcinoma cells: a comparative study with normal placental cells. Mol Cell Endocrinol (1990) 0.76
Regional expression of the BCRP/ABCG2 transporter in term human placentas. Reprod Toxicol (2013) 0.76